Novo Nordisk launches obesity drug Wegovy in China at prices lower than in the U.S.

Novo Nordisk has launched Wegovy, its top-selling obesity drug, in China at prices significantly lower than in the US. Initial prescriptions will be available in Shanghai, though the drug is not covered by China's national health insurance. Wegovy's third-quarter sales brought in $2.5 billion for Novo Nordisk, and the company is exploring ways to make the drug more affordable in China, including through commercial insurance.

November 18, 2024
12 Articles